Gene Therapy Could Emerge as a DMD Treatment in 2023
Michael Kelly, MD, chief scientific officer at CureDuchenne, says a gene therapy for DMD could win FDA approval as early as 2023.
CureDuchenne FUTURES National Conference 2022
Complete Coverage
An Interview With CureDuchenne Chief Scientific Officer Dr. Michael Kelly
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Michael Kelly, PhD, chief scientific officer at CureDuchenne, on treatments for DMD.
Patient Advocates Seek to Raise Awareness of DMD Among Spanish Speakers
Thousands of families affected by Duchenne in the US and Latin America face the extra hurdle of accessing reliable information on the disorder in Spanish.
Nonprofit Group Team Joseph Helps Meet the Needs of Patients With DMD
The nonprofit Team Joseph raises money for scientific studies, but also looks for immediate gaps or needs not being met by other patient organizations.
An Interview With Marissa Penrod, Founder of DMD Nonprofit Group Team Joseph
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews Marissa Penrod, founder of the Indiana-based nonprofit group Team Joseph.
New-Generation Gene Therapy for DMD Designed to Elicit Minimal Immune Response
A new-generation gene therapy to treat DMD was introduced at the CureDuchenne 2022 FUTURES National Conference.
CureDuchenne Conference Underscores Role of Parents as Caregivers
The speakers at a CureDuchenne FUTURES conference session I took in were mothers of children and an adult with Duchenne muscular dystrophy (DMD).
Gene Therapy Shows Promise for DMD, as Trials Continue and Challenges Remain
The different types of gene therapy to treat Duchenne muscular dystrophy (DMD) were outlined at a symposium at the CureDuchenne 2022 FUTURES conference.
CureDuchenne Conference Confirms What I Know, Adds More Insight Into a DMD Life
Three medical providers gave presentations on how to balance these factors with the lifestyles that surround Duchenne muscular dystrophy (DMD).
Rationale Introduced on Mechanisms of Dystrophin Restoration to Treat DMD
The session discussed the rationale behind the mechanisms of endogenous dystrophin restoration for the treatment of DMD.
The Present and Future of Vamorolone for DMD
The present and future of vamorolone were described at the CureDuchenne 2022 FUTURES National Conference by Santhera’s patient advocacy lead.
CureDuchenne Holding National DMD Conference in May 2022
CureDuchenne’s national FUTURES conference on DMD will be held between May 27, 2022, and May 29, 2022, in Orlando, Florida, and virtually.
Rare Disease Advisor is excited to offer coverage of CureDuchenne’s 2022 FUTURES National Conference. The CureDuchenne 2022 FUTURES National Conference is a hybrid virtual/in-person event being held in Orlando, Florida from May 27-29. This year’s conference agenda and special events will focus on Building Community. CureDuchenne will be offering insightful and interactive presentations on a variety of relevant topics, an Exhibitor Showcase, social events for the whole family, e-Gaming experiences, and more.
For registration and program info, visit the FUTURES 2022 info page.
- Loading...
Loading...
Want to read more?
Please login or register first to view this content.
Next post in DMD Features
Loading... 
Loading...